Posters

Amaris hyperopic treatments in Epi-LASEK with MMC

Poster Details

First Author: M. Camellin ITALY

Co Author(s):    S. Mosquera                    

Abstract Details

Purpose:

To determine safety and outcomes of hyperopic corrections in Epi-LASEK by using MMC 0,02% for 2 min.

Setting:

DR. Massimo Camellin, Sekal Rovigo Microsurgery Centre, Rovigo, Italy

Methods:

34 eyes receiving hyperopic corrections in Epi-LASEK with the prophylactic coadyuvant use of MMC 0,02% for 2 min have been analysed and compared to a historic cohort of hyperopic corrections in Epi-LASEK with the prophylactic coadyuvant use of MMC 0,01% for 10 seconds.

Results:

There was no difference in pain or reepithelisation time between groups. There was significant difference in haze development between both groups (p<0.05). No patient in MMC0,02%x2m group developed haze beyond grade 1+ vs. 7% patients in MMC0,01%x10s, 88% in MMC0,02%x2m group developed haze grade 0.5 or below vs. 70% patients in MMC0,01%x10s (p<0.05).

Conclusions:

The prophylactic use of MMC 0,02% for 2 min seems to be advantageous in the prevention of Haze in epi-LASEK hyperopic corrections. As there is skepticism in doing hyperopic surface ablation, it is important underline that with MMC 0,2% for 2 min the results are excellent.Particularly, the typical haze (arcuate) ring virtually disappears.

Financial Disclosure:

NONE